Overview

DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.

Phase:

Phase 2

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborators:

AstraZeneca
Daiichi Sankyo Co., Ltd.

Treatments:

Camptothecin
Immunoconjugates
Trastuzumab